GE HealthCare to Feature Latest Technologies in Interventional Radiology Focused on Precision Care at SIR 2024
22 3월 2024 - 11:51PM
Business Wire
- Multi-modality showcase brings hands-on experience to care
delivery for a wide range of vascular diseases and health
conditions
- Scientific studies provide evidence that Embo ASSIST solution
can help clinicians reduce patient dose, fluoroscopy time and
overall procedure time while performing prostate artery
embolization (PAE)
GE HealthCare (Nasdaq: GEHC) will showcase its latest
technologies in image guiding solutions, surgery, ultrasound and
CT-navigation at the upcoming 2024 Society of Interventional
Radiology (SIR) Annual Scientific Meeting taking place March 23-28
in Salt Lake City, UT. The multi-modality showcase will feature
innovations focused on precision care delivery for a wide range of
vascular diseases and health conditions.
In today’s practice of interventional radiology, clinicians use
image guiding technologies to deliver targeted, minimally invasive
treatments to help treat a wide range of medical conditions – from
cancer care and vascular disease to common health concerns that
affect quality of life for both men and women alike. Among the
emerging treatments in interventional radiology today, prostatic
artery embolization (PAE) has been shown to be an effective
treatment for symptomatic benign prostatic hyperplasia (BPH), or an
enlarged prostate - the most common prostate condition for men
older than age 50.1 The procedure involves targeted release of
microscopic particles into the arteries that feed the prostate. The
particles stop blood flow into the gland helping to decrease its
size and relieve troubling BPH symptoms without any cutting, use of
laser or tissue removal. In order for the PAE procedure to be
successful, clinicians need to be able to identify the correct
arteries and vascular anatomy feeding the prostate in order to
deliver precise and targeted treatment.
As GE HealthCare continues to advance the Allia IGS
platform and interventional innovation, Embo ASSIST AI
is the latest addition to the company's ASSIST imaging
software. Embo ASSIST AI builds on Embo ASSIST software with
AI-based automation designed to automatically segment vascular
structures to facilitate embolization workflow planning, as well as
help clinicians visualize and anticipate the destination of
potential injections.
Scientific studies have shown that the use of Embo ASSIST
enables users performing PAE to:
- Reduce patient dose by 44% (Air Kerma) and 58% (Peak Skin
Dose);2
- Reduce fluoroscopy time by 27% and overall procedure time by 21
minutes (20%);2
- Improve anatomy understanding in 46% of cases versus raw
cone-beam computed tomography (CBCT), with four times more
secondary branches found versus digital subtraction angiography
(DSA);3 and
- Reduce PAE patient dose (DAP) by 70% and improved PAE technical
success from 70% without software to 90% with software.4
Embo ASSIST has also been shown to support the development of
emerging procedures including rectal artery embolization for
hemorrhoidal disease5 as well as intra-arterial chemotherapy
infusion in patients with skull base tumors.6
“With GE HealthCare’s Allia IGS platform and innovative
solutions like Embo ASSIST, we’re able to bring the best possible
care to the patients we serve,” says Dr. Jafar Golzarian of North
Star Vascular and Interventional who was part of the first team in
the United States to perform a PAE procedure.7 8 “This technology
gives us real-time image guidance to deliver precise, targeted and
more complete treatments for a wide range of complex diseases and
conditions. As an interventionalist who performs a number of
different procedures in my daily practice, including PAE, the
system is incredibly flexible and provides a number of workflow
efficiencies that can be personalized to address my specific needs
and preferences around patient positioning and access to help
achieve enhanced patient comfort, as well as improved clinical and
operational outcomes in my practice.”
GE HealthCare designed the Allia IGS Platform to provide
workflow efficiency, functionality, and versatility that
interventional radiologists require in order to meet the needs of
their patients:
“As a leader in the interventional space,” said Arnaud Marie –
Global General Manager for Image Guiding Solutions at GE
HealthCare, “these latest innovations show just what’s possible in
the delivery of precision care and demonstrates our commitment to
advancing the practice of image guided therapy with artificial
intelligence and digitization for clinicians and their
patients.”
As part of this year’s showcase, GE HealthCare will be
exhibiting the following medical devices and digital solutions at
SIR 2024 (Booth 520):
- Image guiding solutions including the Allia IGS
platform designed to be a trusted assistant for image guided
therapies with features to enhance user experience and improve
workflow integration and efficiency; and ASSIST solutions
that leverage advanced digitization and AI to help clinicians
precisely plan, guide and assess interventional procedures with
greater precision and dose efficiency.
- OEC 3D surgical imaging C-arm provides precise 3D and 2D
imaging to surgical suites while enabling efficient imaging every
day. Based on GE HealthCare’s proven AW image fabric technology,
the OEC 3D C-arm enables clinicians to quickly capture and analyze
2D as well as precise 3D volumetric images with a C-arm, bringing
CT-like images into the operating room.
- CT-Navigation offers clinicians detailed, real-time, 3D
CT images for stereotactic needle guidance across an array of care
areas, including interventional and oncological procedures as well
as biopsies, ablations, drainage, therapeutics and more.
- LOGIQ E10: Part of the elevated LOGIQ portfolio,
LOGIQ E10 includes innovative new features and advanced artificial
intelligence (AI) tools designed to address the evolving needs of
healthcare providers with easy imaging, efficient workflow and
Verisound digital and AI solutions including reporting, fleet
management and collaboration tools. LOGIQ E10 also integrates
wireless, dual-probe Vscan Air CL—which is well-suited for
interventional superficial procedures—for wireless
flexibility.
GE HealthCare will also be hosting in-booth educational
discussions throughout SIR 2024, including:
- “How to Adapt Advanced Imaging with CBCT Fusion for Vascular
Malformation Procedures” with Dr. Michael Miller9 on Sunday,
March 24 from 2:30 - 3:00pm MT.
- “AI Guidance for Prostate Artery Embolization” with Dr.
Jafar Golzarian on Monday, March 25 from 12:00 – 1:00pm MT.
- “Interventional CT: CT guidance assisted by electromagnetic
navigation for percutaneous interventions” with Dr. Francois
Cornelis10 on Monday, March 25 from 2:30 - 3:00pm.
- “How Do I Do It: Genicular Artery Embolization” with Dr.
Jafar Golzarian on Tuesday, March 26 from 9:45 - 10:45am MT.
- “Imaging Optimization in Vascular Malformations” with
Dr. Michael Miller on Tuesday, March 26 from 2:30 - 3:00pm MT.
For more information, visit the GE HealthCare website here.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology,
pharmaceutical diagnostics, and digital solutions innovator,
dedicated to providing integrated solutions, services, and data
analytics to make hospitals more efficient, clinicians more
effective, therapies more precise, and patients healthier and
happier. Serving patients and providers for more than 100 years, GE
HealthCare is advancing personalized, connected, and compassionate
care, while simplifying the patient’s journey across the care
pathway. Together our Imaging, Ultrasound, Patient Care Solutions,
and Pharmaceutical Diagnostics businesses help improve patient care
from diagnosis, to therapy, to monitoring. We are a $19.6 billion
business with 51,000 colleagues working to create a world where
healthcare has no limits.
Follow us on Facebook, LinkedIn, Twitter, Instagram, and
Insights for the latest news, or visit our website
https://www.gehealthcare.com/ for more information.
-
https://www.niddk.nih.gov/health-information/urologic-diseases/prostate-problems/prostate-enlargement-benign-prostatic-hyperplasia
- Barral M, Lassalle L, Gardavaud F, Lehrer R, Haffaf I, Agbonon
R, Cussenot O, Cornelis FH. Virtual Injection Software Reduces
Radiation Exposure and Procedural Time of Prostatic Artery
Embolization Performed with Cone-Beam CT. J Vasc Interv Radiol.
2024 Mar;35(3):409-415. doi: 10.1016/j.jvir.2023.11.012. Epub 2023
Nov 25. PMID: 38008376. This study was supported by a research
grant from GE HealthCare. Dr. Barral and Dr. Cornelis consult with
GE HealthCare. The statements made by Dr. Cornelis et al are based
on his opinions and on results that were achieved in his unique
setting. Since there is no “typical” hospital, and many variables
exist — e.g., hospital size, case mix, etc. — there can be no
guarantee that other customers will achieve the same results.
- Abstract No. 149 Impact of Cone-Beam CT and Augmented Planning
on Complete Prostatic Vascular Anatomy Identification for Prostatic
Artery Embolization - Journal of Vascular and Interventional
Radiology
(https://www.jvir.org/article/S1051-0443(22)01629-3/fulltext).
This study was supported by a research grant from GE HealthCare.
Dr. Carnevale consults with GE HealthCare. The statements made by
Dr. Carnevale et al are based on his opinions and on results that
were achieved in his unique setting. Since there is no “typical”
hospital, and many variables exist — e.g., hospital size, case mix,
etc. — there can be no guarantee that other customers will achieve
the same results.
- Abstract No. 227 Use of dedicated planning and guidance
software results in radiation dose reduction in prostate artery
embolization - Journal of Vascular and Interventional Radiology -
Journal of Vascular and Interventional Radiology
(https://www.jvir.org/article/S1051-0443(21)00618-7/fulltext).
This study was supported by a research grant from GE HealthCare.
Dr. McClure consults with GE HealthCare. Raphael Doustaly was a GE
HealthCare employee at the time of the study. The statements made
by Dr. McClure et al are based on his opinions and on results that
were achieved in his unique setting. Since there is no “typical”
hospital, and many variables exist — e.g., hospital size, case mix,
etc. — there can be no guarantee that other customers will achieve
the same results.
- Rectal Artery Embolization for Hemorrhoidal Disease - Anatomy,
Evaluation, and Treatment Techniques
(https://pubs.rsna.org/doi/full/10.1148/rg.220014) Dr. Vidal
consults with GE HealthCare. The statements made by Dr. Vidal et al
are based on his opinions and on results that were achieved in his
unique setting. Since there is no “typical” hospital, and many
variables exist — e.g., hospital size, case mix, etc. — there can
be no guarantee that other customers will achieve the same
results.
- Feasibility and Safety of Cone-Beam Computed Tomography
Advanced Navigation to Optimize Intra-arterial Chemotherapy
Infusion of Skull Base Tumors
(https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-2257-5590).
This study was supported by a research grant from GE HealthCare.
Dr. Cornelis consults with GE HealthCare. The statements made by
Dr. Cornelis et al are based on their opinions and on results that
were achieved in his unique setting. Since there is no “typical”
hospital, and many variables exist — e.g., hospital size, case mix,
etc. — there can be no guarantee that other customers will achieve
the same results.
- Paid consultant: Dr. Jafar Golzarian is a paid consultant for
GE HealthCare. The statements made by Dr. Golzarian here are based
on his own opinions and on results that were achieved in his unique
setting. Since there is no “typical” hospital, and many variables
exist — e.g., hospital size, case mix, etc. — there can be no
guarantee that other customers will achieve the same results.
-
https://www.mhealthfairview.org/treatments/Prostate-Artery-Embolization#:~:text=Prostate%20Artery%20Embolization%20has%20been,in%202012%20with%20excellent%20results.
- Paid consultant: Dr. Michael Miller is a paid consultant for GE
HealthCare. The statements made by Dr. Miller here are based on his
own opinions and on results that were achieved in his unique
setting. Since there is no “typical” hospital, and many variables
exist — e.g., hospital size, case mix, etc. — there can be no
guarantee that other customers will achieve the same results.
- Paid consultant: Dr. Francois Cornelis is a paid consultant for
GE HealthCare. The statements made by Dr. Cornelis here are based
on his own opinions and on results that were achieved in his unique
setting. Since there is no “typical” hospital, and many variables
exist — e.g., hospital size, case mix, etc. — there can be no
guarantee that other customers will achieve the same results
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240321971237/en/
Emily Niles Global Communications Leader – Image Guided Therapy
GE HealthCare +1 262 290 8089 emily.niles@gehealthcare.com
GE HealthCare Technologies (NASDAQ:GEHC)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
GE HealthCare Technologies (NASDAQ:GEHC)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024